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Medicines shortages (stock-outs) have been cited as a complex global 
problem. Evidence suggests that the causes vary greatly and include 
issues that government agencies often do not have control over, such 
as supplier shortages.[1] Stock-outs appear to be worsening with 
time globally, which presents a threat to patient wellbeing and could 
result in loss of life.[2] At a global level, multi-stakeholder activities 
to evaluate the causes of stock-outs and to develop appropriate 
mitigating strategies have been initiated.[2]
Like many other countries, South Africa (SA) has experienced 
several stock-outs of life-saving medicines. There has also been 
a spate of media reports on stock-outs of essential medicines for 
treatment of HIV and major chronic non-communicable diseases.[3,4] 
A 2012 publication by the National Department of Health (NDoH) [5] 
reported a 54% failure in compliance with measures addressing 
availability of medicines and recommended priority attention to 
supply chain management. Local research has found that confidence 
in the public sector has waned as a result of stock-outs.[6]
These and other ongoing challenges in the SA medicines supply 
chain served as the impetus to investigate the supply chain and to 
identify barriers to access to medicines (ATM) and existing strategies 
for improving ATM under the Accessing Medicines in Africa and 
South Asia project.[7] In this quest, we acknowledged that ATM 
barriers are multi-layered, with overlapping and interconnected 
causes,[2,8] and that the supply chain in SA is diverse and complex. 
Notwithstanding these complexities, it is expected to reliably supply 
pharmaceuticals from manufacturers to provincial depots and sub-
depots (in some cases), and directly or indirectly to all levels of health 
facilities, centralised dispensaries and other non-health facilities. 
This is crucial for meeting the growing demand for medicines, 
particularly for treatment of chronic diseases, among others.[9] Given 
the various interconnections in the supply chain, our approach was to 
investigate how the complex interplay of ATM dimensions, including 
pharmaceutical regulation, medicines distribution and demand-
side barriers, influenced ATM in SA. We selected tracer medicines 
commonly used in the public sector that could aid in identifying 
the relevant issues in the supply chain. These were rifampicin 
(antituberculosis), metformin (antidiabetic, type 2), lamivudine 
(antiretroviral), fluoxetine (antidepressant) and oxytocin (labour 
induction).[7]
Previous articles emanating from this research reported on 
policy implications for medicine registration[10] and equity in the 
geographical distribution of community pharmacies in SA.[11] We 
also identified supply and demand barriers to ATM[12] and existing 
strategies for mitigating these barriers.[12,13] In the Western Cape 
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Conclusion. Addressing the procurement challenges, most notably timeous tender awards and supplier performance management, is 
critical for successful implementation of ATM strategies.
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(WC) Province, we identified two distinct strategies for improving 
ATM: the Chronic Dispensing Unit (CDU) and community-based 
medicines delivery models. The CDU, a model for centralised 
dis pensing of medicines in the public sector, was introduced to 
address the shortage of pharmacists, reduce patient waiting times 
and decongest health facilities.[13-15] Community-based medicines 
delivery models were aimed at distributing medicines closer to 
patients’ homes, thereby addressing barriers associated with physical 
accessibility and affordability of transport costs. These models are 
fully described elsewhere.[16-18] Despite these advances in the WC, 
public sector stock-outs hampered the efficiency of ATM strategies 
and disrupted service provision. Among the reasons offered for 
stock-outs were inefficiencies in procurement, a centralised function. 
In this article we therefore demonstrate how inefficient procurement 
processes have undermined ATM.
Medicines procurement in SA
Procurement of medicines in SA is centralised and managed by the 
NDoH, with some variation in organisation between procurement of 
HIV medicines and that of other medicines. Pharmaceutical tenders 
are advertised, awarded and monitored by the NDoH. Provinces 
submit quantification figures to the NDoH for the contract period, 
where the figures are then aggregated. Contracted suppliers deliver 
directly to depots and in some cases (for selected items) directly to 
the CDU and health facilities.
Methods
This qualitative study was conducted between 2012 and 2014 with 
a purposeful sample of over 70 key informants representing front-
line health workers, sub-structure and provincial level health service 
managers.
Application of the critical incident technique
We employed the critical incident technique[19] to identify occurrences 
that have special significance in our context. The method focuses 
on gathering data that are potentially useful in solving practical 
problems. Critical incidents were described by Flanagan[19] as:
• an extreme behaviour, either outstandingly effective or ineffective 
with respect to attaining the general aims of an activity
• an incident that is complete in itself to permit inferences and 
predictions to be made, and the consequences of which are 
sufficiently definite to leave little doubt concerning its effects.
In this research, the critical incident was defined as any such incident 
having special significance in our context.
Data collection. The critical incident technique consists of a set 
of procedures for collecting information that allow participants to ‘tell 
the story’ (what) and then generate details by posing probing ‘when’, 
‘where’ and ‘why’ questions. The technique is commonly used to 
collect data on observations previously made that are reported from 
memory – which is usually satisfactory when the incidents reported 
are fairly recent. However, in some situations adequate coverage cannot 
be obtained if only very recent incidents are included.[19] As such, we 
requested the informants to reflect on a longer period (5 years) to 
identify incidents positively or negatively affecting ATM. To allow for 
this detailed exploration, we used a semi-structured interview guide 
containing open-ended questions as a data collection tool.
Data analysis. Our process involved listing the incidents identi-
fied, then making a judgement based on the principles of the 
critical incident technique as described earlier. We then developed 
descriptions of the selected incidents.
Ethics approval and consent to participate
Ethics approval for this study was granted by the Senate Research 
Committee of the University of the Western Cape (ref. no. 11/7/8). 
Consent to interview and record interviews was obtained from 
participants. They were also informed of their right to withdraw from 
the interview at any time.
Results
Overview of the general state of medicines  
availability in the WC
Informants recognised the positive role by the WC Department of 
Health in instituting measures to minimise stock-outs in the province. 
They reported that in general, stock-outs at the provincial depot had 
reduced significantly from over 160 out-of-stock items each week 
a few years before to an average of 10 - 20 items at the time of the 
study, some of which could be substituted by the use of different pack 
sizes of the same medicine. Frontline health workers received regular 
updates on the stock situation from the depots, which enabled them 
to make alternative arrangements where possible. Sometimes buffer 
stock was available in the health facilities, enabling pharmacists to 
continue dispensing activities without disruption in the event of 
stock-outs at the depot.
However, poor forecasting at the level of health facilities was 
sometimes regarded as a challenge, particularly during times of policy 
changes or strategic service delivery decisions that led to increased 
demand for specific medicines and medical devices without the 
necessary adjustments to the quantification and ordering processes. 
Such events occurred when health managers developed programmes 
or campaigns and neglected to liaise timeously with the provincial 
supply chain team, which could in turn result in stock-outs. One such 
incident was described by a pharmacy manager as follows:
 ‘… last month we had a problem with Accu-check sticks [for 
blood glucose testing] because the province started testing 
everyone for glucose and nobody told the depot “Listen, we 
need more …”, and the depot didn’t know to tell the company 
[supplier], so now we’ve got this snowball effect and … we don’t 
have enough to give the patient.’
Although the above example referred to medical devices, similar 
experiences occurred with tracer medicines, and the informant raised 
it in that context.
Besides province-specific issues, processes at central level caused 
stock-outs at particular time periods. Two of our tracer medicines, i.e. 
metformin and rifampicin, were affected by these processes, and so 
were other medicines. This in turn had implications for ATM.
Perceived causes of procurement inefficiencies
Stock-outs were attributed to: (i) delay in award of pharmaceutical 
tenders; (ii) removing national contracts for certain medicines 
on provincial code lists; and (iii) supplier failure to meet contract 
obligations. We elaborate on these three factors below, and discuss the 
implications of stock-outs for ATM strategies in the WC.
Delay in award of pharmaceutical tenders
Delayed award of pharmaceutical tenders by the NDoH emerged as 
one of the key challenges facing the pharmaceutical system. Some 
informants attributed tender challenges to a lack of manpower in the 
NDoH to timeously renew tenders – a function previously performed 
by National Treasury. During our research, we witnessed the knock-
on effect of late tender awards in 2012 and 2014. Informants 
reported that this was a common occurrence every 2 years when 
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pharmaceutical contracts expired. By 2014, some informants had 
witnessed the impact of late tender awards over a number of cycles, 
which led to an increase in the number of out-of-stock items.
As indicated by one informant:
 ‘… we had dues out [out-of-stock medicines] down to about 10 
to 15 at one stage for quite a long period at depot side. Now it’s 
started creeping up to 60 … in a crisis 2 years ago it was over 
100. But it is on the increase because of these tender problems.’ 
(Senior provincial manager)
Another informant added:
 ‘Every 2 years when the contracts expire we go through these 
(stock) problems … at the moment we’re sitting with a 66 item 
dues-out at depot [medicines unavailable from the depot], and 
this is because of the tendering system … And that’s the biggest 
gap in the system … they [the NDoH] know exactly when the 
tender is going to end, but the process takes so long. Then they 
have to ask current tender companies to extend their contract 
for 1 or 2 months. The company’s response could be, “I don’t 
want to do it, and I don’t have the capacity.” Then they have to 
look for another company and this usually leads to problems.’ 
(Mid-level manager, district substructure)
In an effort to understand reasons for suppliers’ unwillingness to 
extend contracts, one informant shared the following insights:
 ‘I think there is a lack of understanding with our tender guys 
[procurement officials] that these pharmaceutical manufacturers 
sometimes plan 2 years in advance. And when they plan, when 
they have been allocated the contract that obviously has a major 
impact on their production planning – and we must remember 
that they don’t produce only one item or two items, they’ve got a 
variety of products that they manufacture. They have timeslots 
and certain machines for all these, and one machine might be 
used for two different products. So there are major challenges 
for them as well, but from a planning point of view it really has 
a negative effect on these guys [suppliers].’ (Mid-level manager, 
medicines procurement)
Informants also added that suppliers tend to downscale production 
in the last few months of their contract because of uncertainties 
around successful rebidding. In view of the tough economic climate, 
it is no longer financially viable for suppliers to produce excess stock, 
whereas in the past they held significant amounts of buffer stock, 
allowing them the flexibility to extend their contracts. Suppliers 
are also sometimes reluctant to extend their contracts because of 
the unplanned production upscaling and the associated risk of 
being penalised should they fail to meet the prescribed timelines. 
Interim options to source large volumes of medicine from alternative 
pharmaceutical companies that are not contracted to the NDoH are 
limited, since these companies tend to downscale manufacturing of a 
particular medicine if they fail to secure a national contract.
Absence of national contracts for medicines on the  
provincial code list
According to informants, at times there was poor communication 
between provincial and national stakeholders. A case in point: 
about 70 items were excluded from the most recent national tender 
at the time of the study (2014) without first consulting provinces, 
which was the usual practice in order to allow health providers to 
prepare for the change. Informants thought this action was a result 
of efforts by the NDoH to align medicines tenders to the Essential 
Medicines List. At the same time, a decision was taken to include 
only one item per medicine class, which placed a strain on the 
industry to increase production of these items and also meant that 
there were no alternatives for the provinces in the event of shortages. 
While provinces could lobby for the medicines to be placed back on 
national tender and/or to procure directly from suppliers (sometimes 
involving importation of medicines), these processes often took a 
long time, with resultant delays in supply. In other cases, guideline 
modification through the Provincial Pharmacy and Therapeutics 
Committees was required to allow for medicines substitution. The 
positive note reported by our informants was that the NDoH 
acknowledged the risk of only including one item per class.
Failure by suppliers to meet demand
Suppliers failed to meet contractual obligations due to: (i) global 
shortages of active pharmaceutical ingredients (APIs) (e.g. the 
shortage of APIs for antituberculosis medicines during the study 
period); and (ii) lack of capacity, especially during the start-up phase, 
after a contract is awarded, when demanders procure large volumes 
to compensate for stock-outs imposed by delayed contracting. 
General capacity constraints also became evident during the course 
of the contract when a supplier failed to meet demands, and although 
these incidents were reported to the NDoH, it was not unusual for 
the contractor to be reappointed during the next tender cycle. One 
informant said:
 ‘We are tied [left with no option] … the most we can do is 
inform the National Department of Health that they have been 
bad suppliers … but history has shown us and our experience 
has shown us that those suppliers do get reappointed with 
contracts again and we sit with the same problems again.’ (Mid-
level manager, medicines procurement)
When a supplier provides a substandard/inferior product and a 
medicine recall ensues, a severe disruption in supply may result. An 
incident cited by informants was when the state received supplies 
of rifampicin tablets containing substantially less than the specified 
amount of active ingredient.
Implications of stock-outs for ATM strategies
Strategies for improving ATM in the WC were affected by stock-outs. 
First, the CDU system, which dispenses medicines for over 300 000 
patients, operates on a set production schedule and stock received 
after commencement of the production process cannot be introduced 
into the dispensing system. Stock-outs resulted in batches of patient 
medicine parcels (PMPs) being dispatched to health facilities without 
all the prescribed medicines. Consequently, pharmacists at health 
facilities manually dispensed the missing medicines from buffer 
stock or provided alternative therapy under the authorisation of 
a prescriber. Owing to the high burden of chronic diseases in the 
province, this meant that several hundreds of PMPs at each health 
facility required additional medicines. While it was commendable 
that health facilities sometimes had buffer stock that allowed them 
to minimise the impact of stock-outs on patients, workload in the 
pharmacies increased due to the additional dispensing tasks and 
caused frustration among pharmacists. Accordingly, patient waiting 
times increased. In instances where no buffer stock was available, 
patients had to return at a later date when the medicine was expected 
to be available. Also, community-based services rely on the CDUs’ 
prepacked PMPs, and these services were affected when stock-outs 
occurred. Stock-outs caused service interruption, forcing patients 
who benefited from community-based services to attend the health 
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facility for their medicine supply. This imposed additional transport 
costs on patients and is likely to have impacted negatively on their 
welfare.
Stock-holding at depots (up to 6 months) and health facilities 
(4 - 8 weeks) generally created a buffer to procurement and other 
challenges in medicine supply, ensuring that patients had access 
to their medicines. In recognising the importance of maintaining 
buffer stock, there were some concerns that the recommendation 
from the NDoH for the public sector to migrate to a ‘push’ model, 
which supplies pre-defined and standard volumes of medicine down 
to health facilities based on demand planning, as opposed to a ‘pull’ 
model, which relies on orders from health facilities, could preclude 
holding buffer stock.
Discussion
The challenges imposed by stock-outs are becoming more evident 
against the backdrop of increased demand for chronic disease 
treatment in SA,[20] but they are not new.[21] While some studies have 
reported that pharmaceutical systems in low- and middle-income 
countries are generally strained and weak,[22-24] there has been a 
limited focus on procurement processes, yet the critical incidents 
identified in our study were linked to this issue.
The interconnected nature of different levels of the health system 
(provincial and national) was clear. Based on the issues raised by 
this research, minimising stock-outs requires action at a national 
level, where procurement takes place, to ensure that tenders are 
awarded timeously and supplier performance is monitored. Also, the 
provinces (not only the WC) have a responsibility to provide accurate 
forecasts to the NDoH.
Existing ATM strategies[13-17] depend on a consistent, secure 
and reliable source of medicines to function optimally, yet they 
are regularly interrupted by stock-outs. Addressing the prevailing 
challenges will be of benefit to the country as a whole given that 
medicines will continue to play an integral role in the health system, 
not only of the individual provinces but also to achieve the ATM 
goals under the proposed National Health Insurance scheme in 
SA.[25]
Conclusion
Addressing causes of stock-outs, starting at the national level, is 
critical for successful implementation of ATM strategies in SA and 
to ensure that patient care is not adversely affected. The recurrence 
of stock-outs due to predictable events warrants continued attention 
to the underlying issues. Addressing the procurement challenges, 
most notably timeous tender awards and supplier performance 
management, is critical for successful implementation of ATM 
strategies.
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